Rapport Therapeutics (RAPP) KOL event summary

Introduction and agenda

• The event focused on bipolar mania and the RAP-219 clinical program, featuring perspectives from leading experts and company leadership, with a Q&A session for analysts.

• The agenda included an overview of RAP-219, background on bipolar mania, review of trial design, discussion of upcoming milestones, and market opportunity.

• Covered company and RAP-219 overview, disease state and treatment landscape, Phase 2 trial design, and Q&A.

KOL background and credentials

• Dr. Mauricio Tohen is a University Distinguished Professor, Chair of Psychiatry at UNM, and President of the American Association of Chairs of Departments of Psychiatry.

• Mauricio Tohen, MD, DrPH, MBA, is a distinguished professor and chairman at the University of New Mexico Health Science Center, with extensive experience in bipolar disorder research.

• Dr. Gary Sachs is Founding Director of the Bipolar Clinic at MGH, Associate Clinical Professor at Harvard, and led the NIMH STEP-BD program.

• Gary Sachs, MD, is the founding director of the Bipolar Clinic at Massachusetts General Hospital and an associate professor at Harvard Medical School.

Market insights and analysis

• Bipolar disorder affects about 1% of the population, with high lethality due to suicide and significant comorbidities, including substance use and medical conditions.

• Bipolar mania affects about 1.6M patients in the US, with a $45B market opportunity due to unmet needs and limitations of current therapies.

• Diagnosis is challenging due to lack of biomarkers, leading to delays in treatment and high rates of misdiagnosis.

• Current treatments are limited by side effects, poor tolerability, and low adherence, with a significant unmet need for better, faster-acting, and long-acting options.

• The U.S. market for bipolar mania is estimated at 1.6 million patients, with a broader $2–2.5 billion opportunity in epilepsy that could double with a long-acting injectable.

• Current standard of care is limited by metabolic and neurological side effects, leading to poor compliance and limited long-term use.